Search results
Results From The WOW.Com Content Network
Vasopressin is used to manage anti-diuretic hormone deficiency. It has off-label uses and is used in the treatment of gastrointestinal bleeding, ventricular tachycardia and ventricular defibrillation. Vasopressin is used to treat diabetes insipidus related to low levels of antidiuretic hormone. It is available as Pressyn. [6]
Vasopressin is released into the brain in a circadian rhythm by neurons of the suprachiasmatic nucleus. [21] Vasopressin released from posterior pituitary is associated with nausea. [22] Recent evidence suggests that vasopressin may have analgesic effects. The analgesia effects of vasopressin were found to be dependent on both stress and sex. [23]
Its effects are opposite that of a diuretic. The major endogenous antidiuretics are antidiuretic hormone (ADH; also called vasopressin) and oxytocin. Both of those are also used exogenously as medications in people whose bodies need extra help with fluid balance via suppression of diuresis.
This is due to a variety of mechanisms including: stimulation of ADH release (opiates, ifosfamide, vincristine, platinum-based antineoplastics and MDMA (also known as ecstasy)); enhancers of ADH effect (non-steroidal anti-inflammatories); ADH analogues (desmopressin, oxytocin); and vasopressin receptor 2 activators (selective serotonin reuptake ...
A vasopressin receptor antagonist (VRA) is an agent that interferes with action at the vasopressin receptors. Most commonly VRAs are used in the treatment of hyponatremia , especially in patients with congestive heart failure , liver cirrhosis or SIADH .
The well known antidiuretic effect of vasopressin occurs via activation of V 2 R. [1] Vasopressin regulates water excretion from the kidney by increasing the osmotic water permeability of the renal collecting duct – an effect that is explained by coupling of the V 2 R with the G s signaling pathway, which activates cAMP.
An antihypotensive, also known as vasopressor, is an agent that raises blood pressure by constricting blood vessels, thereby increasing systemic vascular resistance.This is different from inotropes which increase the force of cardiac contraction.
Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.